KiriGenX™, Inc. is redefining soft-tissue repair in Orthopedics with its flagship innovation, the Kiri-SE™ bioinductive collagen implant. A next-generation biologic engineered to restore tendon integrity and support a faster return to activities. Designed to address a massive unmet need in the multi-billion-dollar rotator cuff repair market, Kiri-SE™ is backed by a world-class Scientific Advisory Board, robust GLP preclinical study, and a clear FDA 510(k) pathway. Positioned for rapid commercialization and strategic acquisition interest, KiriGenX™ aims to establish a new standard in Orthopedic biologics.